KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Travere Therapeutics (TVTX) Assets (2016 - 2025)

Historic Assets for Travere Therapeutics (TVTX) over the last 17 years, with Q3 2025 value amounting to $538.6 million.

  • Travere Therapeutics' Assets rose 677.44% to $538.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $538.6 million, marking a year-over-year increase of 677.44%. This contributed to the annual value of $594.1 million for FY2024, which is 2469.07% down from last year.
  • As of Q3 2025, Travere Therapeutics' Assets stood at $538.6 million, which was up 677.44% from $555.3 million recorded in Q2 2025.
  • Travere Therapeutics' Assets' 5-year high stood at $832.8 million during Q3 2023, with a 5-year trough of $504.4 million in Q3 2024.
  • Moreover, its 5-year median value for Assets was $736.4 million (2023), whereas its average is $694.3 million.
  • Per our database at Business Quant, Travere Therapeutics' Assets surged by 3332.65% in 2021 and then crashed by 3943.57% in 2024.
  • Travere Therapeutics' Assets (Quarter) stood at $776.6 million in 2021, then decreased by 13.4% to $672.6 million in 2022, then rose by 17.3% to $788.9 million in 2023, then dropped by 24.69% to $594.1 million in 2024, then decreased by 9.35% to $538.6 million in 2025.
  • Its Assets was $538.6 million in Q3 2025, compared to $555.3 million in Q2 2025 and $548.8 million in Q1 2025.